Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Phase II Study to Evaluate the Response Rate to the Licensed Single-Dose Polysaccharide Pneumococcal Vaccine Pneumovax 23™ (MSD Aventis Pasteur) in Elderly Population.

NCT00307008 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00307008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00307008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Phase II Study to Evaluate the Response Rate to the Licensed Single-Dose Polysaccharide Pneumococcal Vaccine Pneumovax 23™ (MSD Aventis Pasteur) in Elderly Population.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2003
Completion date
February 28, 2005
Enrollment
1,198 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

streptococcus pneumoniae vaccines